Sharemaestro Newsreel

Why AbbVie (ABBV) Stock Is Up Today

AbbVie (ABBV) stock rose 3.3% today, driven by positive Wall Street sentiment and anticipation of its second-quarter earnings report. Analyst price target increases and new regulatory submissions for drugs like RINVOQ and SKYRIZI indicate strong pipeline momentum, despite ongoing challenges with Humira. Investors are …

Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer

Biogen Inc. has appointed Michael J. Parini as its new chief legal officer, effective August 3rd, where he will oversee the company's global legal and compliance functions and report to the CEO. Parini brings over two decades of experience in the biopharmaceutical industry, having …

Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement

Merck & Co Inc (MRK) stock rose by 3.24% on July 16, driven by optimism regarding its late-stage oncology pipeline, strategic advancements in its immunology portfolio, and diversification efforts. Analysts have increased price targets, citing strong performance in its vaccine and animal health segments. …

AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?

AbbVie Inc.'s stock (ABBV) rose by 3.32% due to positive clinical trial outcomes for Skyrizi and Rinvoq, reinforcing its post-Humira growth strategy. Institutional investors are favoring healthcare stocks like AbbVie for its dividend profile and resilient cash flow, amidst a broader market shift from …

GSK plc (NYSE: GSK) insiders add ADSs through dividend reinvestment

GSK plc reported that several senior leaders and non-executive directors acquired American Depositary Shares (ADS) between July 10 and July 14, 2026. These acquisitions were a result of the automatic reinvestment of cash dividends paid to shareholders on July 9, 2026, with ADS prices …

Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?

Pfizer's stock is trading below its 50-day and 200-day simple moving averages, indicating investor caution due to declining COVID-related revenues and upcoming patent expirations. Despite these challenges and a dull 2026 financial outlook, the company is rebuilding its pipeline in oncology and obesity through …

Amarin (NASDAQ: AMRN) CLO gets RSU shares; some withheld for tax

Jonathan Provoost, EVP and Chief Legal Officer of Amarin Corporation, reported RSU activity where he acquired 3,688 American Depositary Shares (ADS) and had 1,264 ADS withheld for tax obligations, which is not considered a market sale. This activity relates to a 7,376-unit RSU grant …

Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com

Grifols has announced the dosing of the first patients in two Phase 3 clinical trials for its immunoglobulin therapeutics, GAMUNEX-C and XEMBIFY. These trials aim to expand the U.S. labels for these treatments, with one focusing on secondary immunodeficiency in blood cancer patients and …

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

This article compares Johnson & Johnson and Eli Lilly and Company, two major pharmaceutical giants, as potential investments in 2026. While Johnson & Johnson offers stability and diversification across medical technology and pharmaceuticals, Eli Lilly presents a high-growth opportunity driven by its dominant position …

The Real Engine Behind Johnson & Johnson Stock’s Next Climb

Johnson & Johnson (JNJ) stock has paused after a significant run-up, leading investors to question its next growth driver. The article suggests that while one segment faces a slowdown, the Innovative Medicine division, excluding the impact of STELARA, achieved double-digit growth. This strong performance, …

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD) has garnered investor attention, with its stock performing well recently. The article discusses factors influencing its future performance, including revisions to earnings estimates, projected revenue growth, past financial results, and valuation metrics. Zacks currently rates Gilead as a Zacks Rank #3 …

J&J’s DePuy Synthes acquires spine implant maker Expanding Innovations

Johnson & Johnson's DePuy Synthes has acquired Expanding Innovations, a company specializing in expandable implant technology for spine surgery, to strengthen its spine portfolio and expand its presence in the expandable interbody cage segment. Expanding Innovations' proprietary non-screw-based interbody cage technology is designed to …

Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion

Eli Lilly has acquired AtaiBeckley, a developer of psychedelic therapies, for up to $3.8 billion. The deal includes an upfront payment of $2.8 billion and up to an additional $1 billion in milestone-based payments for AtaiBeckley's lead candidates, intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression …

Merck stock steadies as investors track its drug pipeline

Merck & Co. (MRK) stock is currently steady, with investors focusing on its drug pipeline and upcoming earnings given its status as a prominent U.S. pharmaceutical company. The company's business revolves around prescription medicines, particularly in oncology and vaccines, making late-stage development crucial for …

J&J sees Spravato sales surge as psychedelic competitors loom

Johnson & Johnson's depression drug Spravato saw a 40% Q2 revenue increase, reaching $584 million, marking it as a key franchise with potential peak sales of $5 billion. While psychedelic treatments like Compass Pathways' COMP360 and Definium Therapeutics' DT120 show promising clinical results and …

Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion

Eli Lilly has announced an agreement to acquire AtaiBeckley, a mental-health-focused pharmaceutical company, for an initial sum of $2.8 billion. This deal, part of Eli Lilly's recent acquisition trend, involves paying $6.75 per share in cash, representing a 26% premium over AtaiBeckley's previous closing …

Grifols Trial Could Expand Treatment Options for 60,000 Patients

Grifols has initiated two new Phase 3 trials, SIGMA and XPERT, to expand the U.S. indications for its flagship immunoglobulins, GAMUNEX-C and XEMBIFY. The SIGMA trial focuses on preventing infections in hematologic cancer patients with secondary immunodeficiency, while XPERT aims to demonstrate XEMBIFY's non-inferiority …

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, along with its licensee Genevant, has filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. The company also announced it received approximately $178 million from Moderna as part of a settlement …

Merck cholesterol drug, Lipfendra, approved by FDA (MRK:NYSE)

Merck's oral PCSK9 inhibitor, Lipfendra (enlicitide), has received FDA approval for adults with high cholesterol levels. The drug aims to reduce low-density lipoprotein cholesterol, commonly known as bad cholesterol. This approval provides a new treatment option for managing high cholesterol.

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Eli Lilly and Company is set to acquire AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing therapies for mental health conditions, including treatment-resistant depression. The acquisition will expand Lilly's neuroscience pipeline, with AtaiBeckley's lead asset, BPL-003, already having U.S. FDA Breakthrough Therapy Designation and …

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck announced the FDA approval of LIPFENDRA (enlicitide) tablets, the first and only once-daily oral PCSK9 inhibitor for reducing LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). This approval is based on results from the CORALreef Lipids and CORALreef HeFH Phase 3 …

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion to expand into psychedelic treatments for mental health disorders, a sector gaining interest with increased federal support. The deal, valued at $6.75 per share, gives Lilly access to AtaiBeckley's leading candidate, BPL-003, a psychedelic-based …

Merck's cholesterol pill gets US FDA approval

Merck has received U.S. FDA approval for its new cholesterol pill, Lipfendra (enlicitide), marking it as the first oral PCSK9 inhibitor to gain such regulatory clearance. This approval is a significant step for Merck in diversifying its portfolio beyond its successful cancer drug Keytruda, …

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

Eli Lilly announced its acquisition of psychedelic drugmaker AtaiBeckley for $2.8 billion, aiming to expand its offerings in mental health treatments. This deal gives Lilly access to AtaiBeckley's experimental DMT-based drug, BPL-003, which is currently in Phase 3 clinical trials for treatment-resistant depression, with …

AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

Shares of AtaiBeckley surged 50% premarket after a report indicated Eli Lilly was in talks to acquire the psychedelic drug developer this week. The potential deal could be worth over $2 billion, following an industry-wide rally spurred by a U.S. executive order aiming to …

Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow?

AbbVie (ABBV) stock has achieved a 150.7% return over five years, presenting a mixed valuation picture. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 46.4% due to strong cash flow and recent Tepkinly approval, market-based multiples, specifically the P/E …

Novo's Wegovy pill cleared for weight loss in EU

The European Commission has approved Novo Nordisk’s oral formulation of the weight-loss therapy Wegovy, making it the first oral GLP-1 agonist for obesity and overweight patients in the EU. This approval follows the drug's launch in the UK, UAE, and its existing presence in …

D.A. Davidson & CO. Trims Stake in Amgen Inc. $AMGN

D.A. Davidson & CO. reduced its stake in Amgen Inc. by 2.7% in the first quarter, selling 6,632 shares and retaining 241,522 shares valued at approximately $84.98 million. Amgen exceeded first-quarter earnings expectations, reporting an EPS of $5.15 on revenue of $8.62 billion, a …

Sanofi joins the mRNA vaccine patent wars

Sanofi has initiated lawsuits against Pfizer and Moderna, alleging infringement of its patents related to the delivery of messenger RNA using lipid nanoparticles in their COVID-19 and RSV vaccines. Acquired through the 2021 Translate Bio purchase, these patents represent Sanofi's strategy to gain value …

Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in Amgen Inc. by 2.9% in the first quarter, selling over 113,000 shares, though still holding 3.79 million shares valued at $1.33 billion. Amgen reported strong Q1 earnings, surpassing revenue and EPS expectations. Analyst sentiment …

Organon Suspends Earnings Calls While Sun Pharma Deal Is Pending

Is Biogen (BIIB) a Buy, Hold, or Sell Right Now

Biogen (BIIB) faces a complex market, balancing declining legacy revenue with promising new Alzheimer's and rare disease therapies. Despite a mixed analyst sentiment, recent upgrades and a significant potential upside to the consensus price target suggest cautious optimism. Investors should evaluate Biogen's strong valuation …

Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson (NYSE: JNJ) experienced a nearly 10% stock pullback after its latest earnings report, which analysts view as a buying opportunity due to strong fundamentals and an outlook including revenue surpassing $100 billion. The company reported $25.31 billion in quarterly revenue and …

Sanofi, Lilly back AdvanCell's $315M radiopharmaceutical push

The article reports that Sanofi and Lilly are investing in AdvanCell's $315 million radiopharmaceutical initiative. This significant backing from major pharmaceutical companies highlights growing interest and investment in radiopharmaceutical development. The collaboration aims to advance AdvanCell's efforts in this specialized area of medicine.

Earnings Preview: Novartis AG to Report Financial Results on July 21

Novartis AG (NYSE:NVS) is scheduled to announce its quarterly earnings results on Friday, July 21st. The company has a history of meeting or beating analyst estimates and currently has a consensus EPS estimate of $1.76 and a revenue estimate of $13.56 billion for the …

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin Corporation plc (NASDAQ: AMRN) has announced that it will release its second quarter 2026 financial results and host a conference call on Wednesday, July 29, 2026. The company will issue a press release before market hours, followed by a call with senior management …